Viral vectors having enhanced effectiveness with reduced virulence
US6846652B2 · kind B2 · utility
16Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2001 |
| Grant date | Jan 25, 2005 |
| Priority date | — |
| Expiry date | Feb 23, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising the recombinant vaccinia virus are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.